Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis

BACKGROUND: Crizanlizumab was approved by the United States Food and Drug Administration agency in 2019 for decreasing vaso-occlusive events (VOEs) in sickle cell disease (SCD). Data regarding the use of crizanlizumab in the real-world setting are limited. Our goal was to identify patterns of crizan...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheplowitz, Halle, Block, Shanna, Groesbeck, Jessica, Sacknoff, Stefanie, Nguyen, Anthony L., Gopal, Srila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332863/
https://www.ncbi.nlm.nih.gov/pubmed/37435415
http://dx.doi.org/10.14740/jh1127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332863/
https://www.ncbi.nlm.nih.gov/pubmed/37435415
http://dx.doi.org/10.14740/jh1127

Ejemplares similares